Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 3:39 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 13,745 matching trials from the live ClinicalTrials.gov search.

Filters: Baltimore, Maryland Clear all

Conditions: Immunoglobulin A Nephropathy, Glomerular Disease, IgAN
Interventions: Dose-Placebo, Low Dose-VIS649, Medium Dose-VIS649, High Dose-VIS649; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 17
States / cities: Birmingham, Alabama • Los Angeles, California • Oxnard, California + 13 more

Conditions: Exercise, Mobile Health, Pregnancy, Gestational Diabetes
Interventions: Monitored, At-Home Exercise Intervention; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Lyme Disease
Interventions: MicroB-plex Lyme Immunoassay; Diagnostic Test
Lead sponsor: MicroB-plex, Inc.; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Fall Prevention, Falls
Interventions: Steady Strides; Other
Lead sponsor: Steady Strides: Fall Prevention and Stroke Rehabilitation Medical Institute; Industry
Eligibility: 65 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Nerve Compression
Interventions: MRI; Radiation
Lead sponsor: Medical University of Vienna; Other
Eligibility: 18 Years to 45 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Kidney Disease, Nephropathy, Type 2 Diabetes
Interventions: losartan, lisinopril; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 1,448 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 30
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 27 more

Conditions: Dental Caries of Root Surface, Surgery
Interventions: Making impression at surgery; Device
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: Lebrikizumab, Pirfenidone, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 40 Years and older
Enrollment: 505 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 54
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 47 more

Conditions: Locally Advanced or Metastatic Unresectable Urothelial Cancer
Interventions: Sacituzumab Govitecan-hziy, Paclitaxel, Docetaxel, Vinflunine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 711 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 21
States / cities: Phoenix, Arizona • Los Angeles, California • Orange, California + 17 more

Conditions: Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Interventions: Remote monitoring; Behavioral
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 80 Years
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 5
States / cities: Baltimore, Maryland • New York, New York • Chapel Hill, North Carolina + 2 more

Conditions: Unresectable Metastatic Colorectal Cancer, Unresectable Locally Advanced Colorectal Cancer
Interventions: STC-1010 + IS regimen + SOC therapy; Biological
Lead sponsor: Brenus Pharma; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Infections
Interventions: Calanolide A; Drug
Lead sponsor: Sarawak MediChem Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 9
States / cities: Miami, Florida • Vero Beach, Florida • Chicago, Illinois + 6 more

Conditions: Herpes Simplex, HIV Infections
Interventions: Trifluridine, Bacitracin zinc/Polymyxin B sulfate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1992
U.S. locations: 8
States / cities: San Francisco, California • Aurora, Colorado • Chicago, Illinois + 3 more

Conditions: Autism Spectrum Disorders
Interventions: Transcranial Direct Current Stimulation (tDCS); Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: 14 Years to 79 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Crohn's Disease, Complex Perianal Fistula
Interventions: Placebo, Darvadstrocel; Other · Biological
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 22
States / cities: San Francisco, California • West Hollywood, California • New Haven, Connecticut + 17 more

Conditions: Prostate Cancer
Interventions: calcitriol, docetaxel; Drug
Lead sponsor: Novacea; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 52
States / cities: Montgomery, Alabama • Scottsdale, Arizona • Tucson, Arizona + 44 more

Conditions: Migraine Disorders
Interventions: Capsaicin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: Not listed
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 14
States / cities: Phoenix, Arizona • Encino, California • Glendale, California + 9 more

Conditions: Duchenne Muscular Dystrophy
Interventions: Eteplirsen, Golodirsen, Casimersen; Drug
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: Male only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2033
U.S. locations: 23
States / cities: Little Rock, Arkansas • Los Angeles, California • Orange, California + 20 more

Conditions: COVID-19
Interventions: Not listed
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Fall Risk
Interventions: Home-based training, Lab-based training; Device
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 60 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Stress-exposed Urban Male Youth
Interventions: Mindfulness-based stress reduction; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: Male only
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Multiple Sclerosis
Interventions: Laquinimod, Placebo, Avonex®; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 31 more

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Sitamaquine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1993
U.S. locations: 2
States / cities: Indianapolis, Indiana • Baltimore, Maryland

Conditions: Chronic Spontaneous Urticaria
Interventions: barzolvolimab, Matching placebo; Biological
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 963 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 58
States / cities: Birmingham, Alabama • Fountain Valley, California • Inglewood, California + 50 more

Search by objective public record fields.

Safety and Efficacy Study of VIS649 for IgA Nephropathy

Monitored Home Exercise in Pregnancy

Novel Diagnostics for Early Lyme Disease

Steady Stride Fall Prevention Protocol vs Standard of Care

Neurologic Examination of Wide and Narrow Tourniquets

VA NEPHRON-D: Diabetes iN Nephropathy Study

Intraoral Imaging at Clinical Crown Lengthening

A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy

First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer

A Study to Evaluate the Safety and Effectiveness of a New Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), (+)-Calanolide A, in HIV-Positive Patients Who Have Never Received Anti-HIV Treatment

Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Disease in Patients With AIDS: Open Label Pilot Study of Topical Trifluridine

Transcranial Direct Current Stimulation and Autism

Long-term Follow-up Study With Darvadstrocel in the Treatment of Complex Perianal Fistula

ASCENT: Androgen Independent Prostate Cancer Study of Calcitriol Enhancing Taxotere

Biomarker Study in Participants With Migraine

A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practice

A Clinical Observational Study of SARS-CoV-2 Specific CD8 T-Cell Responses to COVID-19 Vaccines in Humans

Assessment of Fall Risks and Subject-specific Training for Fall Reduction

Improving Wellness for Young Men

BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)

Escalating Multiple-Dose Safety and Tolerance of WR 6026 Hydrochloride in HIV-Infected Subjects

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria